Syncromune® Presents SYNC-T™ Therapy: Image-Guided Cryolysis and Intratumoral Immunotherapy at CIRSE 2026

ConferenceSYNC-T™ Therapy SV-102Neutral

AI Analysis

Summary

Syncromune's SYNC-T™ Therapy SV-102 was presented at CIRSE 2026 by Dr. Stephen Kee, reviewing Phase 1 findings and the ongoing Phase 2 LEGION-100 trial in metastatic prostate cancer.

Clinical Trial Data

Phase

Phase 2

Importance:2/10

Sentiment:

0.00

conference presentationPhase 1 dataPhase 2 ongoingmetastatic prostate cancerimmunotherapycryolysis

Related Companies

$GTHP

Read the original article

Published by GlobeNewswire Clinical Studies on September 9, 2026 12:30 PM

Read Original